Urologix, Inc. (ULGX) Stock

About Urologix, Inc.

Established in 1991 and headquartered in Minneapolis, Minnesota, Urologix, Inc. specializes in the development, production, promotion, and distribution of minimally invasive medical devices across the United States. The company's innovative solutions target the treatment of obstructions and related symptoms caused by benign prostatic hyperplasia (BPH). Among its key offerings is Cooled ThermoTherapy, a system that precisely applies microwave energy while simultaneously employing a cooling mechanism to safeguard healthy tissues and improve patient comfort. Urologix also provides the Prostiva RF Therapy System, which directs radio frequency energy into the prostate gland. This process works to eliminate problematic prostatic tissue, consequently easing urethral constriction and alleviating BPH-related discomfort. Urologix, Inc. caters to both healthcare professionals and patients.

Urologix, Inc. (ULGX) stock trades at $0.00 with a market capitalization of $2182. The stock is valued at a price-to-earnings (P/E) ratio of 0.00, price-to-book of 0.00, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.00 and $0.01, and currently trades 100.0% below its 52-week high.

On profitability, Urologix, Inc. generates a return on equity (ROE) of 114.29% — well above the market average, a sign of a high-quality business, return on capital employed of -504.00%, an operating margin of -5.56%, a net profit margin of -38.90%.

Official website: www.urologix.com